- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05626205
Psycho-social Intervention With Paro Robotic Seal Focused on Patients With Dementia (PARO)
PARO: Psycho-social Intervention With Paro Robotic Seal Focused on Patients With Dementia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary aim of this study is to evaluate the patient-perceived improvement in terms of quality of life through Quality of Life - Alzheimer's Disease (QoL-AD), following the use of the Paro robot, integrated with traditional intervention carried out within the IRCCS INRCA Alzheimer's Day Center.
The Secondary aims are the evaluation of the improvement in cognitive status of the elderly person with dementia, in terms of orientation, attentional-executive, mnestic and visuospatial functions, detected through the Addenbrooke's Cognitive Examination (ACE-R); the assessment of mood improvement in terms of reduction of anxiety and depression, detected through the Rating Anxiety In Dementia (RAID) scale and the Cornell Scale for Depression in Dementia (CSDD); the assessment of the elderly person's acceptance of the technology through Quebec User Evaluation of Satisfaction (QUEST 2.0), semi-structured interview and analysis of physiological activation during interaction, with the Noldus Face Reader system and direct observation by the operator; the analysis of behavioral symptomatology through Neuropsychiatric Inventory (NPI); the assessment of practitioner's acceptance of technology through Technology Acceptance Model (TAM) and the assessment of job quality through semi-structured interview.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anna Rita Bonfigli
- Phone Number: 00390718003719
- Email: a.bonfigli@inrca.it
Study Contact Backup
- Name: Elvira Maranesi, Eng
- Phone Number: 00390718004767
- Email: e.maranesi@inrca.it
Study Locations
-
-
-
Ancona, Italy
- Recruiting
- IRCCS INRCA Hospital
-
Contact:
- Roberta Bevilacqua
-
Contact:
- Phone Number: 00390718004767
- Email: r.bevilacqua@inrca.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of mild-moderate dementia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM V).
- MMSE between 10 and 24
- Attending the Alzheimer's Day Center since at least 3 months
- Presence of a caregiver
Exclusion Criteria:
- Severe sensory disabilities (visual and auditory)
- Comprehension difficulties
- History of syncopal episodes, epilepsy, and dizziness not controlled pharmacologically
- Severe autonomic system dysfunction
- Severe behavioral syndromes not compensated by medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group
The Experimental Group will receive for 12 weeks a robotic training with Paro robot combined with traditional training.
|
PARO is an advanced interactive robot.
It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
PARO has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment.
PARO can learn to behave in a way that the user prefers, and to respond to its new name.
|
No Intervention: Control Group
The Control Group will receive only the traditional therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in quality of life
Time Frame: baseline, 12 and 24 weeks later
|
This outcome will be assesed by the Quality of life in Alzheimer's Disease (QoL-AD) test.
The QoL-AD is comprised of 13 items (physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores, ability to do things for fun, money and life as a whole).
Response options include 1(poor), 2(fair), 3(good) and 4 (excellent), for a total score of 13-52, with higher scores indicating better QoL.
|
baseline, 12 and 24 weeks later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in cognitive status
Time Frame: baseline, 12 and 24 weeks later
|
This outcome will be assessed by the Addenbrooke's Cognitive Examination (ACE-R).
It contains5 sub-scores, each one representing one cognitivedomain: attention/orientation (18 points), memory(26 points), fluency (14 points), language (26 points)and visuospatial (16 points).
ACE-R maximum score is 100, composed by the addition of the all domains.
is scored out of 100, with a higher score denoting better cognitive function.
|
baseline, 12 and 24 weeks later
|
changes in mood
Time Frame: baseline, 12 and 24 weeks later
|
This outcome will be assessed by the Rating Anxiety In Dementia (RAID). Rating should be based on symptoms and signs occurring during two weeks prior to the interview. No score should be given if symptoms result from physical disability or illness. Total score is the sum of items 1 to 18. A score of 11 or more suggests significant clinical anxiety. |
baseline, 12 and 24 weeks later
|
changes in signs and symptoms of major depression
Time Frame: baseline, 12 and 24 weeks later
|
This outcome will be assessed by the Cornell Scale for Depression in Dementia (CSDD).
Information is elicited through two semi-structured interviews: an interview of an informant and an interview of the patient.
Each item is rated for severity on a scale of 0-2 (0=absent, 1=mild or intermittent, 2=severe).
The item scores are added.
Scores above 10 indicate a probable major depression.
Scores above 18 indicate a definite major depression.
Scores below 6 as a rule are associated with absence of significant depressive symptoms.
|
baseline, 12 and 24 weeks later
|
changes in acceptance of the technology
Time Frame: baseline, 12 and 24 weeks later
|
This outcome will be assessed by the technology through Quebec User Evaluation of Satisfaction (QUEST 2.0).
The QUEST 2.0 evaluates the patient's satisfaction with various assistive technologies.
|
baseline, 12 and 24 weeks later
|
Collaborators and Investigators
Investigators
- Principal Investigator: Roberta Bevilacqua, IRCCS INRCA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INRCA_006_2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on PARO robot
-
University of NebraskaRecruitingPediatric ALL | Child, Hospitalized | Occupational Therapy | Physical Therapy Modalities | Animal Assisted TherapyUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Centre Hospitalier le MansCentre Hospitalier de Chateau du Loir; Centre Hospitalier de Saint Calais; Centre...RecruitingStress | Burnout, Professional | AnxietyFrance
-
Instituto de Mayores y Servicios Sociales (IMSERSO)Asturhealth SL; Servicio de Evaluación y Planificación del Servicio Canario...CompletedNeurocognitive Disorders | Dementia | Mild Cognitive ImpairmentSpain
-
Assistance Publique - Hôpitaux de ParisThe Paul Bennetot FoundationCompletedModerate to Severe DementiaFrance
-
University of NebraskaCompletedCritical Illness | Pediatric ALL | Occupational Therapy | Physical Therapy Modalities | Animal Assisted TherapyUnited States
-
Centre Hospitalier Departemental VendeeTerminated
-
University of PennsylvaniaEnrolling by invitationDelirium | DementiaUnited States
-
Children's Hospital Los AngelesUniversity of Southern CaliforniaCompleted
-
The Third Xiangya Hospital of Central South UniversityCompleted